Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Fibrogen Inc CS (FGEN)

Fibrogen Inc CS (FGEN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,400,855
  • Shares Outstanding, K 92,128
  • Annual Sales, $ 176,320 K
  • Annual Income, $ -189,290 K
  • 60-Month Beta 1.03
  • Price/Sales 13.14
  • Price/Cash Flow N/A
  • Price/Book 5.93
Trade FGEN with:

Options Overview

Details
  • Implied Volatility 103.33%
  • Historical Volatility 47.42%
  • IV Percentile 94%
  • IV Rank 56.73%
  • IV High 146.22% on 12/17/20
  • IV Low 47.11% on 06/17/20
  • Put/Call Vol Ratio 1.02
  • Today's Volume 528
  • Volume Avg (30-Day) 1,396
  • Put/Call OI Ratio 0.34
  • Today's Open Interest 50,179
  • Open Int (30-Day) 39,103

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate -0.46
  • Number of Estimates 8
  • High Estimate 0.93
  • Low Estimate -0.98
  • Prior Year -0.95
  • Growth Rate Est. (year over year) +51.58%

Price Performance

See More
Period Period Low Period High Performance
1-Month
20.24 +28.41%
on 05/17/21
26.51 -1.96%
on 06/14/21
+4.43 (+20.55%)
since 05/14/21
3-Month
18.12 +43.43%
on 04/09/21
36.13 -28.06%
on 04/01/21
-9.16 (-26.06%)
since 03/12/21
52-Week
18.12 +43.43%
on 04/09/21
57.21 -54.57%
on 02/12/21
-12.17 (-31.89%)
since 06/12/20

Most Recent Stories

More News
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in FibroGen, Inc. of Class Action Lawsuit and Upcoming Deadline - FGEN

New York, New York--(Newsfile Corp. - June 12, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN) and certain...

FGEN : 25.57 (-1.88%)
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of FGEN, PCT and ARRY

NEW YORK, NY / ACCESSWIRE / June 11, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate...

FGEN : 25.57 (-1.88%)
PCT : 19.53 (-0.61%)
ARRY : 16.00 (-0.93%)
DEADLINE TODAY: The Schall Law Firm Files Securities Class Action Suit with Extended Class Period Against FibroGen, Inc. and Encourages Investors with Losses in Excess of $250,000 to Contact the Firm

Los Angeles, California--(Newsfile Corp. - June 11, 2021) - The Schall Law Firm announced today that they have filed a securities class action lawsuit on behalf of plaintiff Thomas Leonard against FibroGen,...

FGEN : 25.57 (-1.88%)
CLASS ACTION UPDATE for FGEN, CS and CCXI: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

NEW YORK, NY / ACCESSWIRE / June 11, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders...

FGEN : 25.57 (-1.88%)
CS : 10.69 (-0.09%)
CCXI : 13.49 (+10.76%)
Final Day to Actively Participate: FibroGen, Inc. (FGEN) Class Action - Bronstein, Gewirtz & Grossman, LLC

New York, New York--(Newsfile Corp. - June 11, 2021) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against FibroGen, Inc. ("FibroGen" or "the Company")...

FGEN : 25.57 (-1.88%)
FGEN FINAL DEADLINE TODAY: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages FibroGen, Inc. Investors with Losses to Secure Counsel Before Important June 11 Deadline in Securities Class Action - FGEN

EQNX::TICKER_START EQNX::TICKER_END

FGEN : 25.57 (-1.88%)
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of FGEN, PCT and WISH

NEW YORK, NY / ACCESSWIRE / June 11, 2021 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders...

FGEN : 25.57 (-1.88%)
PCT : 19.53 (-0.61%)
WISH : 11.57 (+15.70%)
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in FibroGen, Inc. of Class Action Lawsuit and Upcoming Deadline - FGEN

/PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN) and certain of its officers.   The class action,...

FGEN : 25.57 (-1.88%)
FibroGen, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm

Investors with over $250,000 in losses are encouraged to contact the firm before June 11, 2021; click here to submit trade information

FGEN : 25.57 (-1.88%)
FibroGen Class Action Reminder

New York, New York--(Newsfile Corp. - June 10, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against FibroGen, Inc. ("FibroGen" or the "Company")...

FGEN : 25.57 (-1.88%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

FibroGen, Inc. is a research-based biotechnology company. It is focused on the discovery, development, and commercialization of therapeutic agents for treatment of anemia, fibrosis, cancer, and other serious unmet medical needs. The Company develops Roxadustat that is in Phase III clinical development...

See More

Key Turning Points

3rd Resistance Point 27.52
2nd Resistance Point 26.81
1st Resistance Point 26.43
Last Price 25.57
1st Support Level 25.34
2nd Support Level 24.63
3rd Support Level 24.25

See More

52-Week High 57.21
Fibonacci 61.8% 42.28
Fibonacci 50% 37.66
Fibonacci 38.2% 33.05
Last Price 25.57
52-Week Low 18.12

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar